Why we Should Opt Out of the Government's New Patient Database
By Edward Hockings,
The Guardian
| 01. 31. 2014
We have until March to opt out of the
care.data initiative. The ‘
theoretical risk’ that we might be re-identified from our personal data once it is made available to third parties is a compelling reason to opt-out. However, this is not the only reason. Care.data is part of a major legislative programme that includes the Clinical Research Practice Datalink (
CRPD) and the
100,000 genome project – through which whole-sequenced genomes will be put to commercial use. These major infrastructural developments have been accompanied by radical changes to privacy law that have resulted in a cultural shift in the governance of information.
These sweeping changes in privacy law were introduced without consultation, and the risks they entail will be borne by those whose medical records may be accessed without their consent. How did we get to this point? Fourteen years ago, written evidence by SmithKline Beecham to the Select Committee on Health, House of Commons, advanced the view that the “
NHS represents a singular but under-utilised resource for population genetics, and healthcare informatics more generally.”...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...